Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Benner, Axel  [Clear All Filters]
2023
Döhner H, Benner A, Ganser A. All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply. Lancet Haematol. 2023;10(9):e707.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Göhring G, Behrens YLisa, Li Z, et al. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2023.
Hütter-Krönke MLuise, Neagoie A, Blau IWolfgang, Wais V, Vuong L, Gantner A, Ahn J, Penack O, Schnell J, Nogai KAxel, et al. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Front Immunol. 2023;14:1174289.
2019
Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, et al. Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019:JCO1901406.
2015
Radujkovic A, Becker N, Benner A, Penack O, Platzbecker U, Stölzel F, Bornhäuser M, Hegenbart U, Ho AD, Dreger P, et al. Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. Oncotarget. 2015.
2014
Dietrich S, Radujkovic A, Stölzel F, Falk CS, Benner A, Schaich M, Bornhäuser M, Ehninger G, Krämer A, Hegenbart U, et al. Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Transplantation. 2014.
2013
Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Porta MGDella, Jadersten M, Verma A, et al. Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. J Clin Oncol. 2013.